ReviewInternational journal of breast cancer2026
The Roles of MicroRNAs, Oncogenes, and Tumor Suppressor Gene Molecular Subtypes of Breast Cancer: Therapeutic Potential of Pharmaceutical and Natural Products.
Review in International journal of breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Roles of MicroRNAs, Oncogenes, and Tumor Suppressor Gene Molecular Subtypes of Breast Cancer: Therapeutic Potential of Pharmaceutical and Natural Products.International journal of breast cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer (BC) is the most common malignancy among women, with 2.3 million new cases and over 670,000 deaths annually. Despite advances in detection and therapy, relapse, metastasis, and resistance remain significant challenges. Tumor suppressor genes (TSGs) regulate abnormal cell division, whereas oncogenes, which arise from proto-oncogenes, can inhibit TSGs and promote cancer progression. MicroRNAs further influence cellular processes in both normal and malignant states. Pharmaceutical agents such as tamoxifen and paclitaxel have demonstrated efficacy, while natural products, including baicalin and ursolic acid, show promise in modulating oncogenic pathways. Understanding BC subtypes is crucial, as they guide prognosis and enable more precise and personalized treatment strategies. These insights emphasize the complex molecular landscape and evolving approaches to BC therapy. Objective: The review was conducted using a defined set of keywords to search PubMed, Web of Science, Embase, Scopus, Google Scholar, and SciSearch databases covering publications from the inception of each database through August 2, 2025. Key Findings: This review outlines BC subtypes and their molecular features, highlighting TSGs, oncogenes, and miRNAs as therapeutic targets. Both synthetic drugs and natural compounds demonstrate potential applications in advancing BC treatment strategies. Conclusion: BC subtypes, defined by morphology and molecular features, remain vital for targeted therapy advancement. TSGs, oncogenes, and miRNAs play key roles in subtype regulation and require further study for precise detection and treatment. Synthetic drugs and natural compounds show promise as therapeutic agents. However, continued molecular research is essential to improve personalized strategies and overcome relapse, metastasis, and resistance in BC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.